A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360, a TOP1i ADC Targeting Claudin 18.2 (CLDN18.2) in Adult Participants with Advanced Solid Tumors
A Phase 3, Double-Blind, Randomized Study of Zolbetuximab in Combination with
Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of
Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction
Adenocarcinoma in Participants Whose Tumors are HER2-negative, Claudin (CLDN)
18.2-positive and PD-L1-positive
Adjuvant Trastuzumab Deruxtecan (Enhertu) + Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2expressing Esophagogastric cancer.
